Rx Industry Post-M&A Integration, Part I
Executive Summary
The long-term market cap of big pharma relies heavily on R&D pipeline valuation. But, in the wake of recent merger activity, most pharma companies have focused on producing short-term cost reductions in order to impress the financial markets. There is a way to reconcile these two, preserving the best of long-term R&D assets while cutting costs in other areas.